SCHEMBL296771

SCHEMBL296771

Nc1ccccc1NC(=O)/C=C/c1ccn(S(=O)(=O)c2ccc(-c3cn[nH]c3)cc2)c1

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 18/20 0.74
HDAC2 Q92769 9/20 0.74
HDAC3 O15379 4/20 0.74
HDAC10 Q969S8 2/20 0.74
HDAC11 Q96DB2 2/20 0.74
HDAC9 Q9UKV0 2/20 0.74
KDM1A O60341 1/20 0.74
HDAC6 Q9UBN7 3/20 0.50
HDAC8 Q9BY41 2/20 0.50
ABL1 P00519 1/20 0.50
EGFR P00533 1/20 0.50
ERBB2 P04626 1/20 0.50
INSR P06213 1/20 0.50
PDGFRB P09619 1/20 0.50
CDK2 P24941 1/20 0.50
PLK1 P53350 1/20 0.50
HDAC4 P56524 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC5 Q9UQL6 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL296772 1.00 HDAC1 (0.74) HDAC1HDAC2HDAC3HDAC10HDAC11
SCHEMBL296414 0.91 HDAC1 (0.61) HDAC1HDAC2HDAC3HDAC10HDAC11
SCHEMBL296413 0.91 HDAC1 (0.61) HDAC1HDAC2HDAC3HDAC10HDAC11
SCHEMBL296420 0.88 HDAC1 (0.79) HDAC1HDAC2HDAC3HDAC10HDAC11
SCHEMBL296419 0.88 HDAC1 (0.79) HDAC1HDAC2HDAC3HDAC10HDAC11
SCHEMBL297354 0.86 HDAC1 (0.77) HDAC1HDAC2HDAC3HDAC10HDAC11
SCHEMBL297353 0.86 HDAC1 (0.77) HDAC1HDAC2HDAC3HDAC10HDAC11
SCHEMBL296466 0.86 HDAC1 (0.57) HDAC1HDAC2HDAC3HDAC10HDAC11
SCHEMBL3136041 0.86 HDAC1 (0.76) HDAC1HDAC2HDAC3HDAC10HDAC11
SCHEMBL3136052 0.86 HDAC1 (0.76) HDAC1HDAC2HDAC3HDAC10HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1725528-B1 SULPHONYLPYRROLES AS HDAC INHIBITORS 4SC AG (DE) 2013-05-29 EP claimed
US-20130079347-A1 NOVEL SULFONYLPYRROLES ALTANA PHARMA AG (DE) 2013-03-28 US claimed
CN-1926103-B Sulfonyl pyrroles as HDAC inhibitors 4SC AG 2012-12-19 CN claimed
US-20110166140-A1 NOVEL SULPHONYLPYRROLES MAIER THOMAS 2011-07-07 US claimed
US-20100261761-A1 Novel Sulfonylpyrroles MAIER THOMAS 2010-10-14 US claimed
US-20100261721-A1 Novel Sulphonylpyrroles MAIER THOMAS 2010-10-14 US claimed
US-20070184979-A1 Novel sulfonylpyrroles ALTANA PHARMA AG (DE) 2007-08-09 US claimed
CN-1926103-A Sulfonyl pyrroles as HDAC inhibitors ALTANA PHARMA AG (DE) 2007-03-07 CN claimed
EP-1725528-A2 SULPHONYLPYRROLES AS HDAC INHIBITORS Altana Pharma AG (DE) 2006-11-29 EP claimed
WO-2005087724-A2 SULPHONYLPYRROLES AS HDAC INHIBITORS ALTANA PHARMA AG (DE) 2005-09-22 WO claimed
WO-2019043176-A2 HDAC INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY 4SC AG (DE) 2019-03-07 WO disclosed
US-8969401-B2 Sulfonylpyrroles 4SC AG (DE) 2015-03-03 US disclosed
US-8557858-B2 (E)-N-(2-amino-phenyl)-3-{1-[4-(l-methyl-1H-pyrazol-4-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide salts 4SC AG (DE) 2013-10-15 US disclosed
EP-1725528-B1 SULPHONYLPYRROLES AS HDAC INHIBITORS 4SC AG (DE) 2013-05-29 EP disclosed
EP-1928826-B1 SULPHONYLPYRROLE HYDROCHLORIDE SALTS AS HISTONE DEACETYLASES INHIBITORS 4SC AG (DE) 2013-04-24 EP disclosed
WO-2007039404-A1 NOVEL SULPHONYLPYRROLES AS INHIBITORS OF HDAC S NOVEL SULPHONYLPYRROLES NYCOMED GMBH (DE) 2007-04-12 WO disclosed
WO-2007039403-A1 SULPHONYLPYRROLE HYDROCHLORIDE SALTS AS HISTONE DEACETYLASES INHIBITORS NYCOMED GMBH (DE) 2007-04-12 WO disclosed
CN-1926103-A Sulfonyl pyrroles as HDAC inhibitors ALTANA PHARMA AG (DE) 2007-03-07 CN disclosed
EP-1725528-A2 SULPHONYLPYRROLES AS HDAC INHIBITORS Altana Pharma AG (DE) 2006-11-29 EP disclosed
WO-2005087724-A2 SULPHONYLPYRROLES AS HDAC INHIBITORS ALTANA PHARMA AG (DE) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070184979-A1 Novel sulfonylpyrroles HDAC1, HDAC4, HDAC3 HDAC1 1/4885HDAC2 5/4885HDAC3 3/4885
US-20110166140-A1 NOVEL SULPHONYLPYRROLES HDAC1, HDAC3, HDAC2 HDAC1 1/4885HDAC2 3/4885HDAC3 2/4885
US-20100261761-A1 Novel Sulfonylpyrroles HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC2 3/4885HDAC3 1/4885
US-20100261721-A1 Novel Sulphonylpyrroles HDAC1, HDAC3, HDAC2 HDAC1 1/4885HDAC2 3/4885HDAC3 2/4885
US-20130079347-A1 NOVEL SULFONYLPYRROLES HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC2 3/4885HDAC3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.